AR081368A1 - Heterociclilbencil-pirazoles sustituidos y su uso - Google Patents
Heterociclilbencil-pirazoles sustituidos y su usoInfo
- Publication number
- AR081368A1 AR081368A1 ARP110101533A ARP110101533A AR081368A1 AR 081368 A1 AR081368 A1 AR 081368A1 AR P110101533 A ARP110101533 A AR P110101533A AR P110101533 A ARP110101533 A AR P110101533A AR 081368 A1 AR081368 A1 AR 081368A1
- Authority
- AR
- Argentina
- Prior art keywords
- diyl
- diseases
- prevention
- treatment
- well
- Prior art date
Links
- -1 trifluoromethoxy, trifluoromethylsulfanyl Chemical group 0.000 abstract 7
- 238000011282 treatment Methods 0.000 abstract 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 230000006806 disease prevention Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 230000006978 adaptation Effects 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000001146 hypoxic effect Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10004855 | 2010-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081368A1 true AR081368A1 (es) | 2012-08-29 |
Family
ID=44063276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101533A AR081368A1 (es) | 2010-05-08 | 2011-05-04 | Heterociclilbencil-pirazoles sustituidos y su uso |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20130172311A1 (https=) |
| EP (1) | EP2569312B1 (https=) |
| JP (1) | JP5727002B2 (https=) |
| KR (1) | KR20130108997A (https=) |
| CN (1) | CN103003269B (https=) |
| AR (1) | AR081368A1 (https=) |
| AU (1) | AU2011252223A1 (https=) |
| BR (1) | BR112012028651A2 (https=) |
| CA (1) | CA2798375A1 (https=) |
| CO (1) | CO6640218A2 (https=) |
| CR (1) | CR20120570A (https=) |
| CU (1) | CU20120157A7 (https=) |
| DO (1) | DOP2012000284A (https=) |
| EA (1) | EA201291167A1 (https=) |
| EC (1) | ECSP12012288A (https=) |
| ES (1) | ES2462522T3 (https=) |
| IL (1) | IL222851A0 (https=) |
| MA (1) | MA34939B1 (https=) |
| MX (1) | MX2012012960A (https=) |
| PE (1) | PE20130228A1 (https=) |
| PH (1) | PH12012502202A1 (https=) |
| SG (1) | SG185459A1 (https=) |
| TN (1) | TN2012000531A1 (https=) |
| TW (1) | TW201200510A (https=) |
| UY (1) | UY33369A (https=) |
| WO (1) | WO2011141326A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2685875C (en) * | 2007-05-01 | 2015-10-06 | Hill's Pet Nutrition, Inc. | Methods and compositions for diagnosing osteoarthritis in a feline |
| CA2687306A1 (en) * | 2007-05-18 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| PE20130228A1 (es) * | 2010-05-08 | 2013-03-15 | Bayer Ip Gmbh | Heterociclilbencilpirazoles sustituidos |
| EP2867230B1 (en) | 2012-07-02 | 2020-02-12 | Monsanto Technology LLC | Process for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles |
| EP2888253A4 (en) * | 2012-08-24 | 2016-01-06 | Univ Texas | HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES |
| US20140073634A1 (en) * | 2012-08-24 | 2014-03-13 | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center | Heterocyclic modulators of hif activity for treatment of disease |
| ES2691643T3 (es) | 2012-08-24 | 2018-11-28 | Board Of Regents, The University Of Texas System | Moduladores heterocíclicos de la actividad de HIF para el tratamiento de enfermedades |
| WO2015130790A2 (en) | 2014-02-25 | 2015-09-03 | Board Of Regents, University Of Texas System | Salts of heterocyclic modulators of hif activity for treatment of disease |
| US10191597B2 (en) | 2015-06-30 | 2019-01-29 | Synaptics Incorporated | Modulating a reference voltage to preform capacitive sensing |
| KR102544307B1 (ko) * | 2017-01-13 | 2023-06-15 | 닛산 가가쿠 가부시키가이샤 | 방향족 디아민 화합물 전구체의 제조 방법 |
| CN115944626B (zh) * | 2022-12-08 | 2024-04-19 | 桂林医学院附属医院 | 小分子化合物在制备抗缺氧或缺血再灌注损伤药物中的应用 |
| WO2025096662A1 (en) * | 2023-10-30 | 2025-05-08 | Pretzel Therapeutics, Inc. | Compositions and inhibitors of polrmt |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610726B2 (en) * | 2001-06-29 | 2003-08-26 | North Shore-Long Island Jewish Research Institute | Compositions and agents for modulating cellular proliferation and angiogenesis |
| AU2004228057A1 (en) | 2003-04-03 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| AU2004275694B2 (en) | 2003-06-30 | 2008-03-06 | Bizbiotech Co., Ltd. | Compounds, compositions and methods |
| CN1842332A (zh) * | 2003-06-30 | 2006-10-04 | Hif生物公司 | 化合物、组合物及方法 |
| GB0508472D0 (en) * | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| WO2007065010A2 (en) | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
| CA2687306A1 (en) * | 2007-05-18 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| AU2009316019A1 (en) * | 2008-11-14 | 2010-05-20 | Bayer Intellectual Property Gmbh | Heterocyclically substituted aryl compounds as HIF inhibitors |
| DE102008057344A1 (de) * | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung |
| WO2010054764A1 (de) * | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Heteroaromatische verbindungen zur verwendung als hif-inhibitoren |
| EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| ES2405054T3 (es) | 2009-01-23 | 2013-05-30 | Bristol-Myers Squibb Company | Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato |
| PE20130228A1 (es) * | 2010-05-08 | 2013-03-15 | Bayer Ip Gmbh | Heterociclilbencilpirazoles sustituidos |
-
2011
- 2011-05-03 PE PE2012002121A patent/PE20130228A1/es not_active Application Discontinuation
- 2011-05-03 AU AU2011252223A patent/AU2011252223A1/en not_active Abandoned
- 2011-05-03 EP EP11716595.1A patent/EP2569312B1/de active Active
- 2011-05-03 JP JP2013509505A patent/JP5727002B2/ja not_active Expired - Fee Related
- 2011-05-03 MX MX2012012960A patent/MX2012012960A/es active IP Right Grant
- 2011-05-03 KR KR1020127032069A patent/KR20130108997A/ko not_active Withdrawn
- 2011-05-03 EA EA201291167A patent/EA201291167A1/ru unknown
- 2011-05-03 PH PH1/2012/502202A patent/PH12012502202A1/en unknown
- 2011-05-03 CA CA2798375A patent/CA2798375A1/en not_active Abandoned
- 2011-05-03 US US13/696,878 patent/US20130172311A1/en not_active Abandoned
- 2011-05-03 WO PCT/EP2011/057021 patent/WO2011141326A1/de not_active Ceased
- 2011-05-03 SG SG2012082145A patent/SG185459A1/en unknown
- 2011-05-03 MA MA35350A patent/MA34939B1/fr unknown
- 2011-05-03 CN CN201180033637.5A patent/CN103003269B/zh not_active Expired - Fee Related
- 2011-05-03 BR BR112012028651A patent/BR112012028651A2/pt not_active IP Right Cessation
- 2011-05-03 ES ES11716595.1T patent/ES2462522T3/es active Active
- 2011-05-04 UY UY0001033369A patent/UY33369A/es not_active Application Discontinuation
- 2011-05-04 AR ARP110101533A patent/AR081368A1/es not_active Application Discontinuation
- 2011-05-06 TW TW100115869A patent/TW201200510A/zh unknown
- 2011-05-09 US US13/103,305 patent/US8470811B2/en not_active Expired - Fee Related
-
2012
- 2012-11-05 IL IL222851A patent/IL222851A0/en unknown
- 2012-11-07 TN TNP2012000531A patent/TN2012000531A1/en unknown
- 2012-11-07 DO DO2012000284A patent/DOP2012000284A/es unknown
- 2012-11-07 CU CU2012000157A patent/CU20120157A7/es unknown
- 2012-11-08 CO CO12201711A patent/CO6640218A2/es not_active Application Discontinuation
- 2012-11-08 CR CR20120570A patent/CR20120570A/es unknown
- 2012-11-08 EC ECSP12012288 patent/ECSP12012288A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20120028950A1 (en) | 2012-02-02 |
| US8470811B2 (en) | 2013-06-25 |
| CU20120157A7 (es) | 2013-03-27 |
| CA2798375A1 (en) | 2011-11-17 |
| CN103003269B (zh) | 2015-11-25 |
| PE20130228A1 (es) | 2013-03-15 |
| JP2013526497A (ja) | 2013-06-24 |
| PH12012502202A1 (en) | 2013-02-04 |
| SG185459A1 (en) | 2012-12-28 |
| KR20130108997A (ko) | 2013-10-07 |
| EP2569312B1 (de) | 2014-03-26 |
| MX2012012960A (es) | 2012-12-17 |
| EA201291167A1 (ru) | 2013-05-30 |
| US20130172311A1 (en) | 2013-07-04 |
| ECSP12012288A (es) | 2012-12-28 |
| IL222851A0 (en) | 2012-12-31 |
| CR20120570A (es) | 2013-04-22 |
| DOP2012000284A (es) | 2013-03-31 |
| AU2011252223A1 (en) | 2012-12-06 |
| MA34939B1 (fr) | 2014-03-01 |
| ES2462522T3 (es) | 2014-05-23 |
| TW201200510A (en) | 2012-01-01 |
| EP2569312A1 (de) | 2013-03-20 |
| TN2012000531A1 (en) | 2014-04-01 |
| WO2011141326A1 (de) | 2011-11-17 |
| CO6640218A2 (es) | 2013-03-22 |
| UY33369A (es) | 2011-12-01 |
| BR112012028651A2 (pt) | 2016-08-09 |
| JP5727002B2 (ja) | 2015-06-03 |
| CN103003269A (zh) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081368A1 (es) | Heterociclilbencil-pirazoles sustituidos y su uso | |
| CL2013001558A1 (es) | El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico. | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| AR081628A1 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| MX336497B (es) | Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirim idina y su uso como moduladores de los receptores de c5a. | |
| AR071788A1 (es) | Derivados de 3-aminocarbazol, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos para tratar y/o prevenir trastornos asociados con la produccion de prostaglandina e2(pge2), tales como aterosclerosis, artritis, artrosis y tumores, entre otros. | |
| PA8779201A1 (es) | Derivados de piridina | |
| MX2015004771A (es) | Metodos para tratar cancer. | |
| SV2011003802A (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
| CO7101245A2 (es) | Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| DOP2016000047A (es) | Compuestos y composiciones como inhibidores de la mek | |
| CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
| AR088668A1 (es) | Moleculas pequeñas que contienen boro | |
| MX2022001697A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
| CL2008001194A1 (es) | Composicion farmaceutica que comprende florfenico, una ciclodextrina y agua, un solvente y7o una mezcka de los mismos, con al menos 5% de solvente; kit que la contiene; complejo de florfenicol, util para tratr enfermedades respiratorias en animales | |
| BR112013017845A2 (pt) | agente antidiabético de abaixamento de lipídio | |
| UY33075A (es) | Derivados de ciclohexano y usos de los mismos | |
| CL2012001961A1 (es) | Método para tratar una enfermedad o trastorno en que aumentan los niveles de hormonas de estrés y/o disminuyen los niveles de hormonas de andrógenos, en que se administra un compuesto pirrolo-[1,2-c]-imidazol-bencil sustituido; su uso en insuficiencia cardíaca, entre otros; y compuestos pirrolo-[1,2-c]-imidazol-bencil sustituidos. | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| AR099569A1 (es) | Derivados de insulina y los usos médicos de estos | |
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |